17 results about "Interstitial tissue" patented technology

The invention relates to clinical medicine, and more particularly to lymphology, surgery, plastic surgery and oncology, for treating lymphatic swelling in the case of primary or secondary lymphoedema in adults and children, inter alia accompanied by infectious complications, and even more particularly relates to methods for treating lymphoedema and to the use of accessible drugs in the treatment of lymphatic swelling at any stage and in any location. The claimed method for the lymphotropic treatment of lymphoedema involves consecutively preparing an injectable drug composition A containing an adrenergic alpha-1 receptor agonist and a glucocorticoid, administering same by lymphotropic interstitial injection by puncturing the interstitial tissue of the lymphatic region of interest and introducing the drug composition, preparing an injectable drug composition B containing a cholinesterase inhibitor, administering same by lymphotropic interstitial injection by puncturing the interstitial tissue of the lymphatic region of interest and introducing the drug composition, and also, if necessary, preparing an injectable drug composition C containing bovhyaluronidase azoximer, and administering same by interstitial injection by puncturing the interstitial tissue of the lymphatic region of interest. The technical result consists in improving the drainage of free fluid from the tissues and reducing limb swelling in the case of lymphoedema.

Traditionally, the risk or progression of health conditions such as acute kidney injury (AKI) or congenital heart failure (CHF) are evaluated based on laboratory tests. While being worn by a patient, an interstitial patient monitor having a plurality of working electrodes continuously monitors a plurality of analytes in interstitial tissue of a patient. In this way, the interstitial patient monitor can promote early detection of health conditions such as AKI and CHF without laboratory tests.

The invention relates to clinical medicine, and more particularly to lymphology, surgery, plastic surgery and oncology, for treating lymphatic swelling in the case of primary or secondary lymphoedema in adults and children, inter alia accompanied by infectious complications, and even more particularly relates to methods for treating lymphoedema and to the use of accessible drugs in the treatment of lymphatic swelling at any stage and in any location. The claimed method for the lymphotropic treatment of lymphoedema involves consecutively preparing an injectable drug composition A containing an adrenergic alpha-1 receptor agonist and a glucocorticoid, administering same by lymphotropic interstitial injection by puncturing the interstitial tissue of the lymphatic region of interest and introducing the drug composition, preparing an injectable drug composition B containing a cholinesterase inhibitor, administering same by lymphotropic interstitial injection by puncturing the interstitial tissue of the lymphatic region of interest and introducing the drug composition, and also, if necessary, preparing an injectable drug composition C containing bovhyaluronidase azoximer, and administering same by interstitial injection by puncturing the interstitial tissue of the lymphatic region of interest. The technical result consists in improving the drainage of free fluid from the tissues and reducing limb swelling in the case of lymphoedema.

The present invention relates to an ultrasound-responsive nanoprobe and its preparation method and application. The nanoprobe has a core-shell structure, with poly(lactic-co-glycolic acid) and a photosensitizer as the outer shell, and fluorocarbon and tirapazamine as the core. The photosensitizer is a porphyrin derivative, and the fluorocarbon is a low-boiling-point liquid fluorocarbon. Compared with the prior art, the present invention designs an ultrasound-responsive nanoprobe to sensitize hypoxia-specific anti-tumor prodrugs and improve the tumor treatment effect. Among them, the photosensitizer generates ROS under ultrasound triggering while consuming oxygen in the near-vascular oxygen-rich region, thereby deteriorating the hypoxia state of the tumor microenvironment and activating hypoxia-responsive drugs. The huge mechanical force generated by the liquid-gas phase change of the low-boiling-point liquid fluorocarbon under ultrasound triggering can destroy the tumor stromal tissue, promote the penetration depth of the hypoxia-responsive drug at the tumor site, and enable the hypoxia-responsive drug to exert an anti-tumor effect on hypoxic cells far from blood vessels.

This invention relates to a method for simulating the distribution of magnetofluid injection based on the coupling of particle tracking and fluid dynamics, belonging to the field of magnetic nanoparticle movement and particle tracking. The method includes: constructing a two-dimensional geometric model containing healthy tissue, abnormal tissue, and an injection syringe, and setting parameters; constructing a fluid model based on Darcy's law, and calculating the fluid velocity and pressure distribution in the interstitial tissue; coupling the fluid velocity, and solving the diffusion-convection-reaction equation using the finite element method to obtain the macroscopic concentration distribution of the magnetofluid after injection; establishing a particle tracking module, setting discrete particles with the same properties as the magnetic nanoparticles; coupling the interstitial fluid velocity, calculating the drag force and gravity acting on the particles according to Newton's second law, and simulating the particle motion to reveal the microscopic trajectory of the magnetic nanoparticles. This method, by coupling the macroscopic concentration field with the microscopic particle motion, can more realistically simulate the distribution behavior of magnetofluid within complex porous biological tissues.

The invention relates to the technical field of colorectal cancer prognosis, in particular to a colorectal cancer prognosis prediction method and system based on digital pathological image driving. Establishing a first sample data set for training a tissue subtype classification model and a second sample data set for extracting interstitial tissue samples in combination with colorectal cancer public data; training a tissue subtype classification model by using the first sample data set, extracting interstitial tissues in the second sample data set by using the trained tissue subtype classification model, and taking the extracted interstitial tissues as a third sample data set; constructing an interstitial prognosis model according to pathological block prognosis risk assessment positioning task requirements, and training the interstitial prognosis model by using the third sample data set; and extracting interstitial tissue in the pathological image of the target patient by using the trained tissue subtype classification model, and performing risk assessment positioning on the interstitial tissue in the pathological image of the target patient by using the trained interstitial prognosis model so as to perform interpretable analysis on the positioned risk area according to morphology and biology. According to the method, a clinician can be assisted to formulate a more accurate postoperative treatment scheme, and clinical transformation of a deep learning model can be accelerated.

The application discloses a brain-targeting drug delivery system based on a modified outer membrane of Escherichia coli DH5a and a preparation method and application thereof. The drug delivery system is based on specific recognition and combination between outer membrane protein A of the Escherichia coli DH5a and gp96 on endothelial cells of a blood-brain barrier, and mediates the drug delivery system to penetrate the blood-brain barrier and finally distribute in intracranial interstitial tissue. The brain-targeting drug delivery system can penetrate the blood-brain barrier to reach the brain parenchyma through a transcellular vesicular transport pathway, the preparation method is simple, the drug delivery system has good biological safety and superior delivery efficiency, and the drug delivery system has high operability and considerable economic benefits.

The present invention discloses a polypeptide that promotes the proliferation of human umbilical cord mesenchymal stem cells and its application in the in vitro culture of human umbilical cord mesenchymal stem cells. Mesenchymal stem cells have all the characteristics of stem cells, have the potential for self-renewal and multidirectional differentiation, and can differentiate into a variety of mesenchymal tissues, such as bone, cartilage, fat, etc. How to make human umbilical cord mesenchymal stem cells proliferate rapidly in vitro so as to quickly obtain a sufficient number of seed cells in a short time is of great significance. The present invention provides a polypeptide whose sequence is shown in Sequence NO.1, which has an obvious effect of promoting the proliferation of human umbilical cord mesenchymal stem cells in vitro, and will not change the phenotype of human umbilical cord mesenchymal stem cells, and can be used for the efficient in vitro amplification of human umbilical cord mesenchymal stem cells.

The invention discloses a method for culturing vascularization of interstitial-intestinal organs, and belongs to the technical field of biology. The method comprises the following steps: inducing deterministic endoderm; inducing a posterior intestinal endoderm: digesting into single cells and transferring the single cells into an agarose microarray to polymerize into balls; and inducing vascularization of intestinal organs. According to the method for realizing co-differentiation after aggregation of the agarose microarray, the size of the initial intestinal spheroid can be regulated and controlled by adjusting the size of the microarray, and the size of the initial intestinal spheroid is ensured to be consistent; by adjusting the initial cell state, the rapid growth of intestinal organs can be realized, and the growth rate of the polymerized balls is far greater than that of single cells; based on the microarray technology, the problem that the regeneration efficiency is low due to the fact that the spontaneous balling rate of a traditional method is low is solved, the extremely high effective balling rate is achieved, and the intestinal organs with more developed interstitial tissues and the higher vascularization degree are cultivated.

The present invention relates to a method for producing a multi-tissue lung organoid structurally surrounded by fibroblasts, and a use thereof, and provides a three-dimensional structure composed of a lung organoid and a fibroblast layer surrounding the outside thereof. The organoid according to the present invention can maintain a high level of structural stability and bio-fidelity by reproducing a cell arrangement and microenvironment similar to those of actual lung tissue. The multi-tissue organoid more precisely reproduces a microenvironment in which epithelial tissues and interstitial tissues are arranged in layers as in a living body, rather than adopting a simple cell mixing method, and thus can be used in various biomedical applications, such as regenerative medicine, research on lung disease conditions, and evaluation of responsiveness to anticancer drugs and anti-fibrotic drugs. In addition, the present invention has excellent expandability to organoid-on-chip technology or bio-artificial organ development, and thus can be expected to be used as a precision medicine and next-generation cell therapy platform.

The present invention provides the use of Trem2 in the preparation of a reproductive prognosis product for detecting and evaluating cryptorchidism, and relates to the field of biomedical technology. In this application, the role and mechanism of testicular macrophages in the occurrence of cryptorchidism are deeply explored from multiple levels such as molecules, cells, animals, and clinical. A new male reproductive gene, Trem2, is identified by using a variety of technologies including gene knockout mice and fetal testis in vitro culture. In the testicular tissue of the normal group, Trem2 is highly expressed in the seminiferous tubules and interstitium; while in the testicular tissue of cryptorchidism, Trem2 expression is decreased. Dap12, the upstream molecule of Syk, is highly expressed in the testicular tissue of wild-type mice, and in Trem2 ‑ / ‑ Low expression in mouse testis, Trem2 ‑ / ‑ The expression of Insl3 in mice was lower than that in the wild-type group. The study in this application suggested that Trem2 may be involved in the Dap12 / Syk signaling pathway, affecting the testicular descent and sperm development process.

The invention relates to a preparation method of an intercellular substance-containing artificial tissue, which comprises the following steps: introducing a phenylboronic acid group on a protein vesicle by a method of copolymerization of N-isopropylacrylamide and 3-acrylamido phenylboronic acid; the preparation method comprises the following steps: constructing aggregate micro-droplets by taking polydiene dimethyl ammonium chloride and carboxylated amylose as primitives; based on a biological orthogonal reaction of phenylboronic acid and polysaccharide, polysaccharide aggregate droplets are used as intercellular substances to adhere phenylboronic acid modified protein vesicles together to form an aggregate phase with a microstructure similar to that of a biological tissue. According to the method, the problems that the aggregate microdroplets cannot stably exist in an aqueous solution for a long time and the application of the aggregate microdroplets is limited to the micro-scale are solved, a stable aggregate phase can be formed on the macro-scale, and biological enzyme reaction under low concentration is enriched and activated; optimization thoughts in the aspects of consumption saving, enrichment and recovery, enzyme activity regulation and control and the like are provided for some high-value biological enzymes in the using process.

A shunt delivery system includes: a stylet configured to puncture a vein wall, interstitial tissue, and a dura; a dilator including a transverse hollow interior region extending to an aperture in a distal region, the dilator configured to receive the stylet in the hollow interior region and out through the aperture in the distal region, the dilator configured to pass through tissues punctured by the stylet, including the vein wall, the interstitial tissue, and the dura; and a transdural catheter including a hollow interior region configured to receive the stylet, the transdural catheter configured to traverse the tissues dilated by the dilator, including the vein wall, the interstitial tissue, and the dura, such that a distal tip of the transdural catheter is configured to be located in a thecal sac of the patient.

A reinforced arthroscope comprising external ribs to provide for a number of separate fluid channels, such as inflow, outflow and interstitial tissue drainage, when the arthroscope is slipped into a disposable external sheath. The external sheath includes projections that fit closely on either side of one or more of the external ribs to lock the sheath in place circumferentially relative to the arthroscope. The arthroscope is constructed to be sufficiently rigid so as to penetrate and move within a joint without damaging the rod optics inside. The externality of the arthroscope channels allow for cleaning and sterilizing the scope between uses.

A shunt delivery system includes: a stylet configured to puncture a vein wall, interstitial tissue, and a dura; a dilator including a transverse hollow interior region extending to an aperture in a distal region, the dilator configured to receive the stylet in the hollow interior region and out through the aperture in the distal region, the dilator configured to pass through tissues punctured by the stylet, including the vein wall, the interstitial tissue, and the dura; and a transdural catheter including a hollow interior region configured to receive the stylet, the transdural catheter configured to traverse the tissues dilated by the dilator, including the vein wall, the interstitial tissue, and the dura, such that a distal tip of the transdural catheter is configured to be located in a thecal sac of the patient.

A shunt delivery system includes: a stylet configured to puncture a vein wall, interstitial tissue, and a dura; a dilator including a transverse hollow interior region extending to an aperture in a distal region, the dilator configured to receive the stylet in the hollow interior region and out through the aperture in the distal region, the dilator configured to pass through tissues punctured by the stylet, including the vein wall, the interstitial tissue, and the dura; and a transdural catheter including a hollow interior region configured to receive the stylet, the transdural catheter configured to traverse the tissues dilated by the dilator, including the vein wall, the interstitial tissue, and the dura, such that a distal tip of the transdural catheter is configured to be located in a thecal sac of the patient.

The invention discloses a pair of endoscopic tissue space retracting forceps which comprises a control mechanism, a first transmission mechanism, a second transmission mechanism, an elastic mechanism and a protection mechanism, the first transmission mechanism is arranged at the front end of the control mechanism, the second transmission mechanism is arranged in the first transmission mechanism, and the elastic mechanism is arranged at the front end of the control mechanism. The elastic mechanism is arranged above the first transmission mechanism, the anti-skid mechanism is arranged below the front ends of the first transmission mechanism and the elastic mechanism, and the protection mechanism is arranged at the right end of the first transmission mechanism. According to the scheme, through multiple innovative designs such as structure integration and graded buckling, breakthrough is made from four dimensions such as operation stability, the core pain point of an existing instrument is solved, meanwhile, the operation efficiency and operation experience are improved, and a safer and more efficient tissue gap retraction solution is provided for endoscope minimally invasive surgery.